Study of OB-002 in Patients With Refractory Metastatic Cancer

NCT05940844 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped study terminated due to changes in the drug development plan

Conditions

Metastatic Cancer
Metastatic Colorectal Cancer
Metastatic Pancreatic Cancer
Metastatic Gastric Cancer
Metastatic Breast Cancer
Metastatic Urothelial Carcinoma

Interventions

DRUG: OB-002

Sponsor

Orion Biotechnology Polska Sp. z o.o.